prazosin has been researched along with Parkinsonian Disorders in 4 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses in individuals taking TZ and related drugs." | 1.51 | Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. ( Cai, R; Chen, Z; Consiglio, A; Fernandez-Carasa, I; Gao, L; Han, Y; Ji, X; Li, Y; Liu, L; Narayanan, NS; Polgreen, PM; Raya, A; Schultz, JL; Simmering, JE; Su, W; Welsh, MJ; Yuan, Y; Zhang, Y; Zhao, C, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, R | 1 |
| Zhang, Y | 1 |
| Simmering, JE | 1 |
| Schultz, JL | 1 |
| Li, Y | 1 |
| Fernandez-Carasa, I | 1 |
| Consiglio, A | 1 |
| Raya, A | 1 |
| Polgreen, PM | 1 |
| Narayanan, NS | 1 |
| Yuan, Y | 1 |
| Chen, Z | 1 |
| Su, W | 1 |
| Han, Y | 1 |
| Zhao, C | 1 |
| Gao, L | 1 |
| Ji, X | 1 |
| Welsh, MJ | 1 |
| Liu, L | 1 |
| Özkan, M | 1 |
| Johnson, NW | 1 |
| Sehirli, US | 1 |
| Woodhall, GL | 1 |
| Stanford, IM | 1 |
| Archer, T | 1 |
| Fredriksson, A | 1 |
| Seppi, K | 1 |
| Puschban, Z | 1 |
| Stefanova, N | 1 |
| Scherfler, C | 1 |
| Mueller, J | 1 |
| Poewe, W | 1 |
| Wenning, GK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies[NCT04760860] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2024-10-31 | Not yet recruiting | ||
| The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
| Assessing Target Engagement of Terazosin in Healthy Adults[NCT04551040] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-03-26 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for prazosin and Parkinsonian Disorders
| Article | Year |
|---|---|
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Dopamine acting at D1-like, D2-like and α1-adrenergic receptors differentially modulates theta and gamma oscillatory activity in primary motor cortex.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adrenergic alpha-1 Receptor Agonists; Ad | 2017 |
An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Clonidine; Dopamine; Dopamine Agonists; Drug I | 2003 |
Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.
Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Disease Models, | 2001 |